Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — Medical Cannabis Sales Set New Arkansas Record in 2025

Medical cannabis sales in Arkansas reached a new high in 2025. According to data released by the state finance department, patients spent $291.1 million at licensed dispensaries during the year. That total represents a 5.5% increase from 2024 and surpasses the prior record of $283 million achieved in 2023.

Medical dispensaries across Arkansas sold 79,223 pounds of medical cannabis in 2025, an increase of 4.8% from the 75,597 pounds sold in 2024. The state has 37 licensed dispensaries operating statewide.

Since Arkansas launched its medical cannabis program in 2019, total spending at dispensaries has exceeded $1.6 billion, according to DFA spokesperson Scott Hardin.

December proved to be the strongest month of the year, with sales reaching $25.749 million. Several dispensaries stood out for the amount of product sold that month. Suite 443 in Hot Springs led the state with 731.15 pounds sold, followed closely by Natural Relief in Sherwood at 717.83 pounds. CROP in Jonesboro recorded sales of 427.5 pounds, while Custom Cannabis in Alexander and Harvest in Conway sold 411.03 pounds and 410.85 pounds, respectively.

Tax collections tied to medical marijuana also rose alongside sales. Two separate state taxes generated a combined $32.3 million. Since 2019, these taxes have brought in over $218.32 million. Patients pay the standard 6.5 percent state sales tax on each dispensary purchase. In addition, a 4 percent privilege tax applies both to retail sales and to transactions when cultivators sell products to dispensaries.

The state health department also reported growth in the patient base. There were 115,113 medical cannabis cards by December 2025, reflecting a 5.1% increase from February 2025 and an 18.2% rise compared with the start of 2024. The expanding number of qualified patients has helped support steady demand across the state.

Suite 443 opened its doors in May 2019, becoming the first licensed medical marijuana retailer to operate in Arkansas.

Annual sales have climbed steadily since the program began, aside from minor fluctuations. Spending totaled $31.32 million in 2019, rose to $181.8 million in 2020, and continued upward to $264.9 million in 2021 and $276.3 million in 2022 before reaching record territory in subsequent years.

Arkansas voters approved medical cannabis in 2016, passing a constitutional amendment by 53%. The measure legalized cannabis for patients with one or more of 17 qualifying medical conditions and established the framework for state oversight. Much of the tax revenue generated by the program is directed to the University of Arkansas for the Medical Sciences National Cancer Designation Trust Fund, though some collections, such as cultivator privilege taxes, are not directly tied to retail sales or consumer prices.

The success being witnessed in Arkansas is welcome to the entire marijuana industry in and outside the country, including firms like Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF).

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Marijuana Legalization Campaigners in Florida Are Being Arrested

Florida’s push to legalize recreational marijuana has entered a more volatile phase as state officials and campaign organizers trade accusations just weeks before a critical signature deadline.

State AG James Uthmeier stated that his office has opened dozens of new investigations tied to alleged election-related crimes connected to the ballot effort, a move that supporters of the initiative describe as politically motivated.

Smart and Safe Florida, the group leading the legalization push, rejected the claims. The group has until February 1 to deliver more than 880,000 verified signatures from registered voters. If the proposal reaches the ballot, it would still need approval from at least 60% of voters statewide to take effect.

The DeSantis administration has consistently opposed broader cannabis access, and the legalization effort has encountered resistance at nearly every stage. Uthmeier accused 50 individuals hired to collect signatures for the campaign of committing fraud. He alleged that petitions were submitted without voter permission and that some signatures were forged, including names belonging to people who have died.

According to a letter dated January 20 from State Prosecutor Brad McVay, 9 campaign workers have already been taken into custody. McVay also indicated that additional arrest warrants could be issued in the coming days. The same letter requested authorization to issue subpoenas directly to Smart and Safe Florida to examine whether the organization itself violated election statutes.

The expanded criminal inquiry follows reports of mounting pressure on county election offices to invalidate petitions that had already been accepted. Campaign representatives say that they are complying with election rules and flagging any irregularities to state officials as required. A spokesperson suggested that the attorney general’s criticism stems from the campaign’s strict adherence to those regulations.

Legal battles are also playing out in court. Both the campaign and the state are involved in lawsuits over the legitimacy of thousands of signatures already submitted. Last week, a judge in Leon County ordered roughly 29,000 petitions gathered by out-of-state workers to be thrown out. The campaign appealed that decision.

Uthmeier’s role has drawn scrutiny as well. Before becoming attorney general, he served as Gov. Ron DeSantis’ chief of staff during the 2024 election cycle, when cannabis legalization last appeared before voters. During that period, about $10 million from a Medicaid settlement was directed into a political fund overseen by Uthmeier. Advocates for legalization argue that the money was improperly used to campaign against the measure, an accusation the administration has denied.

Florida is currently the nation’s largest medical-use market, making it a key target for companies seeking broader legalization. Still, public support appears to have softened. A recent survey commissioned by the Florida Chamber of Commerce found that only 51% of respondents back legal marijuana, the weakest showing for the idea in four years.

Many firms like Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) are likely to be concerned about the escalating relations between the Florida state government and the advocates seeking to put the legalization measure on the state ballot since ordinary residents could lose out on having their voices heard on the matter.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Recreational Marijuana Legalization Support Dips as Florida Officials Oppose Campaign

Florida officials under Governor Ron DeSantis are stepping up their opposition to a proposed ballot measure that would allow recreational marijuana, drawing county election offices into the fight and prompting accusations that the state is trying to derail the effort before voters weigh in.

Critics say the administration’s actions amount to an aggressive campaign against legalization at a time when public backing appears to be weakening. Florida requires at least 60% voter approval to amend its constitution, and recent polling suggests support for adult-use cannabis is well below that mark.

The latest push comes from Smart and Safe Florida, a group backed largely by Trulieve Cannabis Corp., a multistate cannabis company based in Tallahassee. The group is again seeking to place a legalization amendment on the ballot, this time targeting the 2026 election. A similar attempt in 2024 failed, even after it received a high-profile endorsement from then-presidential candidate Donald Trump.

This election cycle, opponents within the state government have intensified their scrutiny. The DeSantis administration has filed a challenge with the Florida Supreme Court that raises several objections, including concerns tied to marijuana odor.

A poll released by the Florida Chamber of Commerce found that 51% of likely voters support legal recreational marijuana. That figure represents the lowest level of support recorded in four years.

In a statement issued Friday, the Chamber criticized both the initiative and its financial backers. The organization pointed out that over $200 million has been spent over two election cycles to promote legalization, with nearly all of that funding coming from Trulieve, the state’s largest medical cannabis operator. According to the Chamber, polling trends suggest that voter interest declines as people learn more details about the proposal.

Meanwhile, state election authorities have taken steps that supporters of the amendment view as an attempt to slow or block the process. The Office of Election Crimes & Security recently notified election supervisors in three counties that it plans to audit certain approved petition signatures to confirm they were collected legally.

Smart and Safe Florida responded by accusing state leaders of trying to silence more than one million voters who signed petitions in compliance with the law. The group faces a February 1 deadline to submit 880,000 signatures. As of this week, about 675,000 signatures have been validated, according to state records.

Outside Florida, Trulieve continues to expand its footprint. The company recently announced plans to enter the Texas market, where lawmakers are considering changes that would broaden its medical marijuana program.

Entities like Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) in the cannabis industry will be watching how efforts to get adult-use marijuana on this year’s ballot in Florida pan out amid growing opposition from state officials and waning voter support.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — New Study Says No Science Supports Federal Categorization of Marijuana

A new scientific review is challenging the foundations of U.S. drug law, arguing that the legal system governing controlled substances no longer reflects modern scientific understanding of risk.

According to the analysis, drugs such as marijuana are regulated far more harshly than evidence would justify, while substances responsible for widespread harm often face looser oversight or fall outside the system altogether.

American drug policy has largely been shaped by the Controlled Substances Act, passed in 1970. The law created a series of fixed schedules meant to classify drugs based on their danger and potential for abuse. More than five decades later, researchers say those categories have not kept pace with scientific research or real-world outcomes. The new study concludes that official legal rankings frequently clash with expert evaluations of harm, both in the U.S. and internationally.

Despite broad public acceptance and legalization at the state level, marijuana has remained in the most restrictive federal category for years. Although President Donald Trump issued an executive order last month instructing the attorney general to accelerate the process of reclassifying cannabis as a Schedule III drug, the change has yet to be finalized.

To conduct the review, the researchers used a structured evaluation approach known as multi-criteria decision analysis. A group of 17 specialists examined 19 widely used substances, scoring them across 18 measures of harm. These included fatal overdoses, chronic health effects, social disruption, criminal activity, and economic impact. The combined scores produced an overall ranking of harm for each drug.

One of the study’s notable conclusions is that most substances cause more damage to users themselves than to the wider public. That finding, the authors argue, has important implications for how governments respond. They suggest that policies focused on punishment have failed to reduce drug use and have coincided with a surge in overdose deaths. Instead, they call for expanded harm reduction measures.

The authors argue that public funds and attention would be better spent on prevention, treatment, and community health rather than incarceration. They describe a policy environment that has remained largely unchanged while patterns of drug use and harm have shifted dramatically. With fentanyl-related deaths rising and alcohol continuing to cause significant health and social damage, they warn that updating drug laws is no longer a theoretical exercise.

The paper also outlines practical steps tied to its findings. Since fentanyl ranked as the most dangerous substance overall, the researchers point to measures such as wider access to naloxone, drug-checking tools, and supervised consumption sites as evidence-backed responses. They also encourage further studies that consider additional substances, potential therapeutic benefits, vulnerable groups like young people, and different methods of consumption.

This study is likely to trigger plenty of discussion within the scientific community and in marijuana firms like Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) due to the important questions raised about the basis upon which drug laws were formulated.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — UCLA Gets $7.3M in State Grants to Study Marijuana

$7.3 million from the California Cannabis Control Department (DCC). The funding will support studies that examine medical applications of cannabinoids, potential heart-related risks linked to marijuana consumption, and ways to better understand and respond to California’s illegal cannabis market.

Faculty members from multiple UCLA divisions will participate, including researchers from the Fielding School of Public Health, the David Geffen School of Medicine, and the College of Letters and Science.

UCLA Center for Cannabis and Cannabinoids director Ziva Cooper noted that the awards highlight the university’s growing role in marijuana research. She added that UCLA scientists are studying everything from molecular compounds created in the lab to consumer behavior in real-world markets to produce evidence that supports health-focused policy decisions.

The grants account for roughly one-quarter of the $30 million recently distributed by the DCC to nine institutions across the state. The broader initiative is designed to expand scientific knowledge about marijuana and help inform lawmakers and regulators overseeing California’s legal marketplace.

One of the funded projects will focus on synthetic cannabinoids. Granted $2 million, the study will involve creating rare and newly designed cannabinoid compounds in laboratory settings. Researchers will assess their potential medical value, potency, and possible adverse effects. The work is intended to lay the groundwork for future treatments that may be safer or more effective than existing options.

Another $2 million award supports a study of California’s unlicensed marijuana market, which continues to operate years after legalization. Researchers will investigate why many consumers still buy products outside the regulated system. The study will combine fieldwork, surveys, and laboratory testing to identify contaminants and other risks associated with illicit products. Findings are expected to help policymakers develop strategies to reduce harm linked to illegal sales.

A third study will examine how cannabis affects the heart. With $2.1 million in funding, researchers will conduct controlled clinical trials to measure both short-term and longer-lasting cardiovascular effects from smoked and edible marijuana. The results are intended to inform doctors, public health officials, and consumers.

The final project, funded at $1.2 million, centers on marijuana flavoring compounds known as terpenes. Researchers will create a scientific reference library of these substances to help regulators set standards for their use in commercial products. The work aims to reduce health risks and limit marketing practices that could appeal to children.

All four studies are scheduled to launch in early 2026.Their findings could provide insights to marijuana firms in and outside California, such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), in their bid to serve customers better while furthering their business interests.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Survey Finds Americans More Likely to Quit Tobacco, Alcohol Than Cannabis

As the new year begins, many Americans are once again setting personal goals, but a new survey suggests cutting back on cannabis is low on the list compared with other habits. According to recent polling, people are more likely to resolve to drink less alcohol, stop using tobacco, or even spend less time on social media than to scale back cannabis use.

The poll questioned 1,003 adults across the United States about the commitments they plan to make for 2026. Participants were presented with 15 possible resolution categories, ranging from health and fitness to lifestyle habits. Reducing cannabis use emerged as the least popular choice among those options.

Only 8% of respondents said they intended to either stop using cannabis or use it less in 2026. By comparison, 10% reported an intention to reduce alcohol intake, while 12% said they hoped to limit tobacco use. A larger share, 16%, said they planned to rein in their social media habits. The most frequently selected resolution overall was improving physical health at 35%.

Younger adults were somewhat more open to reconsidering their cannabis habits than older age groups. Among people between 21 and 24 years old, 13% said they planned to reduce or quit cannabis use. That share dipped slightly to 12% among those aged 25 to 34 and fell more sharply among older respondents. Just 5% of adults between 45 and 54, and 4% of those 55 and older, expressed the same intention.

Men were twice as likely as women to give up or reduce cannabis use, at 12% versus 6%. Four in 10 respondents who plan to limit cannabis use said they had tried to do so before and were unsuccessful.

When asked why they wanted to reduce their marijuana consumption, more than half said they believed it would increase their flexibility and sense of independence. Around 47% felt it would help them feel more productive or accomplished, while 40% said they expected improvements in mental health, emotional balance, and overall activity levels.

The relatively low interest in quitting marijuana compared with tobacco and alcohol may reflect broader shifts in public perception. While 50% of Americans report having tried cannabis at least once, tobacco and alcohol remain more widely used.

Decades of public health campaigns have also emphasized the risks of drinking and smoking, particularly among younger people. Cannabis, by contrast, remains illegal at the federal level, and nationwide education efforts have been less consistent.

At the same time, recent research indicates shifting consumption patterns. Several surveys suggest that younger adults are increasingly turning to marijuana-infused beverages instead of alcohol, including at social events such as after-work gatherings. Other studies suggest most Americans view cannabis as a less harmful alternative to alcohol and expect nationwide legalization within the next few years.

Entities like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) are likely to analyze the findings of this survey in greater detail in order to glean insights that could inform the firms about the future trajectory of marijuana consumption trends in the country.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Trends Impacting the US Marijuana Industry in 2026

As the legal marijuana sector enters another year of adjustment, new data points show an industry still working to find its footing. While some long-standing challenges remain unresolved, recent developments suggest parts of the market may finally be moving toward a more sustainable balance.

Tax policy remains one of the most consequential issues for cannabis retailers. For years, Section 280E of the federal tax code has prevented marijuana businesses from deducting ordinary operating expenses, including rent, wages, and compliance costs. This framework has routinely pushed otherwise viable stores into the red.

In many established cannabis markets, the tax burden created by 280E has exceeded total net income, effectively eliminating profits altogether. In some cases, the typical dispensary is already losing money before considering expansion or long-term investment.

Analysis from Headset estimates that the rule has added between $400,000 and $800,000 or more in annual tax obligations per dispensary, leaving fewer resources for hiring, infrastructure upgrades, or financial cushions during slow periods. These effects are most pronounced in mature states where competition is fierce and wholesale prices are already compressed.

The situation could soon change following President Donald Trump’s executive order that aims to move marijuana to a new federal classification, opening the door to relief from the 280E restrictions.

Licensing trends tell a different story depending on the segment of the supply chain. Nationwide, the number of active marijuana licenses slipped to 37,555 in 2025’s quarter four, a decline of 1% from Q3. That drop continues a contraction that began in late 2022. Compared with two years ago, total licenses across the country are down 13%.

Most of that reduction has occurred among growers. Since 2023’s Q3, cultivation permits have fallen by 24%, representing a loss of more than 5,000 licenses. Retail permits, by contrast, have been relatively stable, declining by just over 300 during the same time.

Some analysts view the pullback in cultivation as a healthy correction after years of oversupply. At the close of 2025’s Q3, there were approximately 16,000 cultivation licenses and about 11,600 dispensary licenses in the U.S. Canada offers a sharp contrast, with far more storefronts than grow operations.

At the consumer level, discounting remains a dominant strategy. Retailers leaned heavily on promotions throughout 2025 to maintain traffic and move inventory, especially in crowded markets.

In most states, average monthly markdowns on marijuana flower climbed over the course of the year. Washington posted the highest average discount rate at 39%, a figure that may be influenced by its steep 37% retail tax. Arizona followed closely, averaging 35% and briefly peaking near 37% in the spring.

Industry observers expect aggressive promotions to remain common into 2026, as many operators prioritize customer retention and sales volume over margin recovery in an intensely competitive landscape.

Many foreign-based cannabis firms, such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY), will be hoping that conditions improve meaningfully for all licensed firms within the U.S. so that they can not only survive but thrive as well.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Government-Funded Research Says Cannabis Users are Being Wrongfully Jailed for DUI

Government-funded research is raising serious concerns about how cannabis driving laws are being enforced in the United States. According to a new scientific study, many cannabis users are being arrested, charged, and even jailed for driving under the influence despite showing no real signs of being impaired. The research suggests that current DUI laws related to marijuana are not based on sound science and are unfairly punishing innocent people.

In almost 20 U.S. states, lawmakers use what are known as per se or zero-tolerance THC laws. These laws set a fixed amount of THC in the blood that automatically labels a driver as impaired. This system was copied from alcohol laws, where blood alcohol levels are a reliable way to measure intoxication. However, the study shows that cannabis does not work the same way as alcohol in the human body.

THC, the main psychoactive compound in cannabis, behaves very differently from alcohol. Alcohol usually leaves the body within one or two days. THC, on the other hand, can stay in the bloodstream for days or even weeks, especially in regular users. This means a person can test positive for THC long after the effects of cannabis have completely worn off.

To understand this better, researchers studied 190 heavy cannabis users. The participants were asked to stop using cannabis for 48 hours. After this period, their blood THC levels were tested, and they were also observed using a driving simulator. The results showed that many participants still had THC levels above legal limits even though they showed no signs of poor driving or impairment.

The study found no clear link between the amount of THC in a person’s blood and their ability to drive safely. This matches earlier research that also showed weak or inconsistent connections between THC levels and crash risk. While cannabis use may slightly increase the risk of accidents, that risk is much lower than the risk linked to alcohol use.

Medical and laboratory experts have criticized current cannabis DUI laws, saying they lack scientific credibility. They warn that relying only on blood THC levels can lead to innocent people being jailed even when they are sober and driving safely.

The researchers conclude that better methods are needed to identify truly impaired drivers. Instead of depending only on blood tests, they recommend combining roadside observations with toxicology testing. Overall, the National Institutes of Health-funded study highlights a serious flaw in existing cannabis DUI laws and calls for reforms that protect public safety without criminalizing people unfairly.

As drug laws around the country evolve, a bigger task will be to roll back many of the prohibitionist perceptions that show up in different aspects, such as laws that regard traces of THC in blood as proof of intoxication. When these vestiges of prohibition are identified and addressed, the industry and its ecosystem players like Innovative Industrial Properties Inc. (NYSE: IIPR) will move a step closer to truly thriving.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Some Changes Resulting from Marijuana Rescheduling Could Take Time

President Trump’s executive order directing federal agencies to loosen restrictions on marijuana is being welcomed by cannabis businesses and researchers, but experts caution that the practical effects will unfold slowly and unevenly. While the move signals a shift in federal posture, it does not immediately dismantle decades of drug policy.

The order instructs Attorney General Pam Bondi to move marijuana toward Schedule III under federal law, a lower-risk category than its current classification. However, executive action alone does not rewrite the Controlled Substances Act, which has governed drug scheduling since 1970.

According to Gillian Schauer, executive director of the Cannabis Regulators Association, rescheduling typically requires a formal rulemaking process or congressional involvement, neither of which happens overnight.

How quickly the change takes effect depends largely on the path the Justice Department chooses. Bondi could revive a proposal initiated under the previous administration or use a less common provision of federal law that allows faster action. Schauer notes that the accelerated option limits procedural steps but may expose the administration to legal challenges, particularly from groups opposed to loosening marijuana laws.

Public participation could also affect the timeline. A traditional notice-and-comment period would slow the process, while bypassing it could speed implementation. When federal agencies previously floated rescheduling, tens of thousands of public comments poured in, underscoring the political sensitivity surrounding the issue.

For cannabis companies, the most immediate impact could come through taxes. Businesses that sell marijuana currently face higher tax burdens because they are barred from claiming standard deductions. Sam Brill, chief executive of multistate operator Ascend Wellness Holdings, says moving marijuana out of its most restrictive category would eliminate those penalties, easing cash flow and reducing the need to set aside large reserves for potential tax disputes.

Other restrictions are less certain. Even with rescheduling, marijuana would remain illegal to transport across state lines, and access to banking services would likely stay limited. Many financial institutions still avoid the industry, forcing dispensaries to operate largely in cash. Patrick Sims, who owns a dispensary in New York, says the inability to accept credit cards remains one of the biggest barriers for both businesses and customers.

Medical research stands to benefit, though gains may be modest at first. Scientists would no longer need the most restrictive licenses to study marijuana, and laboratory rules would become less burdensome. Neuroscientist Staci Gruber, who studies cannabis at a Harvard-affiliated hospital, has said regulatory requirements have long discouraged researchers from entering the field.

Even so, sourcing marijuana for studies remains tightly controlled by federal agencies, a limitation unaffected by rescheduling. Schauer notes that unless those policies change as well, research will continue to face bottlenecks. Taken together, the executive order marks progress, rather than a clean break from the past. The direction is clear but the pace will depend on legal choices, agency follow-through, and whether broader policy reforms follow.

The entire marijuana industry, including leading companies like TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF), will be hoping that meaningful changes come sooner rather than later so that the regulatory environment is characterized by fewer onerous bottlenecks to businesses.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — UW Scientists Study Health Hazards of Marijuana in Workplaces

Researchers at the University of Washington are taking a close look at the potential health risks for marijuana production workers. A new study from the university’s Department of Environmental and Occupational Health Sciences is examining whether people employed in cannabis cultivation and processing face health risks on the job, particularly those affecting the lungs.

Since recreational and medical marijuana laws began to change across the U.S., cannabis businesses have hired thousands of workers. However, scientists say there is still limited information about the hazards these employees may encounter.

Since cannabis remains illegal at the federal level, formal research into working conditions has lagged behind the industry’s growth. Early warning signs now suggest that airborne particles and other exposures could pose respiratory dangers for some workers.

The study was partly motivated by two deaths in the cannabis sector that investigators linked to job-related asthma. One case occurred in Massachusetts and the other in California.

According to Callan Krevanko, a doctoral student at UW who is coordinating on-site research, cannabis workplaces have not received the same level of scientific scrutiny as more established industries. He noted that the legal status of marijuana discouraged earlier investigation and added that the current effort is among the first to examine these environments in detail.

The research team plans to visit at least ten marijuana operations throughout Washington State, including processing and growing sites, ranging from small businesses to large operations. In total, the researchers expect to collect data from over 100 marijuana production workers.

One of the participating companies is Ferndale-based Subdued Excitement, also known as SubX. Co-founder Nick Cihlar said his company was licensed shortly after Washington voters approved recreational cannabis in 2012, placing it among the early entrants into the legal market.

Cihlar welcomed the study, saying it is reasonable to expect that issues may surface. He suggested that some workers may not consistently use protective gear and that air filtration systems could be inadequate in certain settings. While he stressed that this view is not based on formal evidence, he said the research is necessary to move beyond speculation.

When UW researchers visited SubX in November, they spent a full week inside the facility. Their work included measuring particles in the air, collecting samples from workers’ breathing zones, and conducting health assessments to identify possible symptoms linked to workplace exposure.

Although cannabis businesses fall under oversight from state and federal safety agencies, Cihlar said existing rules are mostly general and not tailored to cannabis production. Tasks such as trimming dried plants can release fine particles into the air, something he believes could affect lung health over time.

Researchers expect to complete their fieldwork this winter. Once the results are analyzed, they plan to offer practical guidance aimed at reducing risk, including improved ventilation strategies and protective equipment that businesses can realistically afford.

The findings could offer some insights to cannabis industry participants like SNDL Inc. (NASDAQ: SNDL) that employ lots of people across their operations.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com